title: [Anti-hypertensive effect of eprosartan in diabetic patients].
abstract: OBJECTIVE
  Diabetes mellitus seems to induce an special difficulty to control the high blood pressure. This effect is more severe on the SBP. Previous reports suggest that a new angiotensin receptor blocker, eprosartan, might have a higher efficacy to reduce SBP. It has been evaluated the BP decrease obtained with eprosartan in a group of diabetics patients compared to non diabetic patients.
  
  
  METHODS
  81 patients were recruited of whom 65 have ended follow-up. 34 patients were diabetics (mean age 66.7+/-10.7 years, 15 men and 19 women) and 31 were non diabetics control patients (mean age 61.8+/-12,8 years, 13 men and 18 women). All patients were treated with (600 mg) once daily. The doses was ingested in the morning. They were made three follow up visits (1, 3 and 6 mo after the first visit).
  
  
  RESULTS
  SBP was significantly decreased both in diabetics (baseline 170.9+/-12.0, final 139.1+/-13.0 mmHg, p < 0.001) and in non diabetics group (baseline 169.9+/-18.0, final 142.0+/-13.3 mmHg, p < 0.001). DBP was also reduced in both groups (diabetics: baseline 92.9+/-9.7, final 78.4+/-8.5 mmHg, p < 0.001; non diabetics: baseline 95.6+/-7.9, final 79.1+/-7.4 mmHg, p < 0.001). Differences between the groups were not significant in any visit. Final BP reduction reached was -31.7/-14.6 mmHg in diabetics vs -27,6/-16,5 mmHg in non diabetics patients (difference is not significant) Pulse pressure changes were not different between the two groups (diabetics, 17.8+/-14.5, vs non diabetics, 11.1+/-13.2 mmHg). Two diabetic patients need a second drug to achieve BP goal and no one in non diabetic group. No adverse effects were reported.
  
  
  CONCLUSIONS
  Eprosartan seems to be an effective drug to reduce SBP, DBP and pulse pressure with the same effectiveness in diabetics and non diabetic patients.
authors.affiliation: Unidad de Hipertensión Arterial, Hospital Infanta Cristina, Centros de Salud, Badajoz, Spain.
authors.forename: N R
authors.initials: NR
authors.lastname: Robles
authors.forename: J
authors.initials: J
authors.lastname: Velasco
authors.forename: J L
authors.initials: JL
authors.lastname: Jiménez Pérez
authors.forename: F J
authors.initials: FJ
authors.lastname: Alonso
authors.forename: J
authors.initials: J
authors.lastname: Blanco
authors.forename: J
authors.initials: J
authors.lastname: Masot
authors.forename: C
authors.initials: C
authors.lastname: Matilla
authors.forename: J
authors.initials: J
authors.lastname: Nieto
authors.forename: F
authors.initials: F
authors.lastname: Romero
authors.forename: M J
authors.initials: MJ
authors.lastname: Gamero
mesh_terms: D000179:Acrylates / Q000627:therapeutic use*; D000368:Aged; D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D048909:Diabetes Complications; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D013876:Thiophenes
chemical_list: D000179:Acrylates; D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D007093:Imidazoles; D013876:Thiophenes; C068373:eprosartan